Investigational Drug Information for Fotemustine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Fotemustine?
Fotemustine is an investigational drug.
There have been 18 clinical trials for Fotemustine.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 29th 2021.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Mingzhi Zhang, Bristol-Myers Squibb, and Zhengzhou University.
There is one US patent protecting this investigational drug and sixteen international patents.
Summary for Fotemustine
| US Patents | 1,025 |
| International Patents | 16,472 |
| US Patent Applications | 4,467 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 2,716 |
| Clinical Trial Progress | Phase 3 (2021-03-29) |
| Vendors | 74 |
Recent Clinical Trials for Fotemustine
| Title | Sponsor | Phase |
|---|---|---|
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | Mingzhi Zhang | Phase 4 |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | Mingzhi Zhang | Phase 4 |
| A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT | Genenta Science | Phase 1/Phase 2 |
Clinical Trial Summary for Fotemustine
Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine
US Patents for Fotemustine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fotemustine | See Plans and Pricing | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | See Plans and Pricing |
| Fotemustine | See Plans and Pricing | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| Fotemustine | See Plans and Pricing | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | Seattle Genetics, Inc. (Bothell, WA) | See Plans and Pricing |
| Fotemustine | See Plans and Pricing | Method of diagnosing and treating cancer using B-catenin splice variants | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | See Plans and Pricing |
| Fotemustine | See Plans and Pricing | Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fotemustine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fotemustine | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | See Plans and Pricing |
| Fotemustine | Australia | AU2015231053 | 2034-03-21 | See Plans and Pricing |
| Fotemustine | Brazil | BR112016021620 | 2034-03-21 | See Plans and Pricing |
| Fotemustine | Canada | CA2943339 | 2034-03-21 | See Plans and Pricing |
| Fotemustine | China | CN106231900 | 2034-03-21 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
